Selecting Therapy in CLL
•Download as PPTX, PDF•
2 likes•2,482 views
A presentation on selecting first line therapy in CLL and how that influences subsequent therapy selection.
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Selecting Therapy in CLL
Similar to Selecting Therapy in CLL (20)
Recently uploaded
Recently uploaded (20)
Selecting Therapy in CLL
- 1. CLL: Past, Present, and Future Jeff Sharman M.D. Medical Director Hematology Research US Oncology http://cll-nhl.com
- 2. CLL: Management in a TKI World • • • • • Historical perspectives FCR – The rise and fall Choosing first line therapy in 2014 Management of relapsed disease Ibrutinib considerations
- 3. CLL: Management in a TKI World • • • • • Historical perspectives FCR – The rise and fall Choosing first line therapy in 2014 Management of relapsed disease Ibrutinib considerations
- 4. Chlorambucil
- 5. Fludarabine
- 8. Improved Outcomes with FCR (2008)
- 9. German CLL8 – FC vs FCR (2003)
- 11. MDA Long Term Follow Up
- 13. So what is the problem?
- 14. FCR not so popular….
- 15. Patterns of Care (FCR in Front Line) • Age < 65 = 45% FCR • Age 65-75 = 32% FCR • Age > 75 = 20% FCR
- 16. Clinical trials versus real life • MDA FCR Median Age – 57 years old • German CLL8 (FC vs FCR) – 61 years old • Real life – Age 71 at diagnosis – Age 74 at first treatment
- 17. Age Matters • Decreased Renal Function – Clears fludarabine • Decreased Marrow Reserves – Prolonged cytopenias – MDS / AML • Infectious Complications – Really nasty gross stuff
- 18. MDA Long Term follow up
- 19. Death within 12 months of first line therapy • MDA = 1% • German CLL8/10 study = 3-4% • Registry Studies = 10%
- 20. Case Study • 72 year old retired lumber yard worker – Lymphocytosis c/w CLL stage I, but over 2 years progressive adenopathy and hemoglobin down to 10 – Deletion 13q but unmutated IgVH • Entered onto FCR vs PCR study – Stopped FCR after cycle 3 due to myelotoxicity – Has maintained remission for six years • Multiple treatment complications – Pulmonary aspergillosis – Received > 50 units PRBC’s over next two years – Now has MDS
- 21. Where will FCR fit in the next five years? ”We’re going to get rid of FCR”
- 23. German CLL10 Study FCR versus BR CIRS < 7, Creatinine Clearance > 70, no 17P deletion FCR BR ORR 97.8% 97.8% CR 47% 38% MRD Negative 71% 66% 2 Year PFS 85% 78%
- 24. German CLL10 Study FCR versus BR CIRS < 7, Creatinine Clearance > 70, no 17P deletion FCR BR G3/4 Neutropenia 82% 56% G3/4 Infection 47% 26% Induction Death 4% 2% Complete 6 cycles 70% 80%
- 25. CLL10 Summary • FCR works a little better, but considerably more toxic than BR • No clear winner as gains in response offset by increased toxicity
- 26. What about the elderly?
- 27. Complement 1 Chlorambucil +/- Ofatumumab Chlorambucil Clb-Ofatumumab PFS (mo) 13 22 ORR 69% 82% CR 1% 12% MRD 4% 12%
- 29. CLL: Management in a TKI World • • • • • Historical perspectives FCR – The rise and fall Choosing first line therapy in 2014 Management of relapsed disease Ibrutinib considerations
- 30. Choosing first line therapy in 2014 FCR BR Age & Comorbidity Obi
- 31. CLL: Management in a TKI World • • • • • Historical perspectives FCR – The rise and fall Choosing first line therapy in 2014 Management of relapsed disease Ibrutinib considerations
- 34. What is “one prior therapy?”
- 35. MRD in CLL8 Study Post 3 cycles End of Treatment
- 36. MRD: Depth = Duration
- 38. CLL: Beyond FISH
- 40. CLL – Evolution in Real Time A: Pre-Chlorambucil B: Pre FCR C: Post FCR D: Pre Ofatumumab E: Post Ofatumumab
- 41. CLL: Management in a TKI World • • • • • Historical perspectives FCR – The rise and fall Choosing first line therapy in 2014 Management of relapsed disease Ibrutinib considerations
- 42. Clinical Challenges • Initial lymphocytosis • Interruptions (surgery / other) • Adherence • Copayments • Adventures in medical decision making • Progressions
- 43. Clinical Challenges • Initial lymphocytosis • Interruptions (surgery / other) • Adherence • Copayments • Adventures in medical decision making • Progressions
- 44. Compartment Effect: Decreased Nodes with Lymphocytosis
- 46. Clinical Challenges • Initial lymphocytosis • Interruptions (surgery / other) • Adherence • Copayments • Adventures in medical decision making • Progressions
- 48. Long Term Drug Problems?
- 49. Clinical Challenges • Initial lymphocytosis • Interruptions (surgery / other) • Adherence • Copayments • Adventures in medical decision making • Progressions
- 50. Clinical Challenges • Initial lymphocytosis • Interruptions (surgery / other) • Adherence • Copayments • Adventures in medical decision making • Progressions